Concepedia

Kyle D. Holen

KD

Statistics

Publications

61

Citations

3.8K

H-Index

34

Active since

2002

Affiliations

University of Wisconsin Carbone Cancer Center(Current)

University of Wisconsin–Madison

AbbVie (United States)

Dana-Farber Cancer Institute

Northwestern University

Kyle D. Holen is an author at University of Wisconsin Carbone Cancer Center specializing in medicine, oncology, and pharmacology.

Publications per year

2002–2021

61

Publications

61

Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors

Kyle D. Holen, David S. Klimstra, Amanda Hummer et al. · Journal of Clinical Oncology · 2002 · 298 citations

, , +16

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor

Kyle D. Holen, Leonard B. Saltz, Ellen Hollywood et al. · Investigational New Drugs · 2007 · 292 citations

, , +14

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

Sam Joseph Lubner, Michelle R. Mahoney, Noelle K. LoConte et al. · Journal of Clinical Oncology · 2010 · 268 citations · Full text

, , +17

MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

Timothy J. Hobday, Joseph Rubin, Kyle D. Holen et al. · Journal of Clinical Oncology · 2007 · 175 citations

, , +16

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu et al. · Clinical Cancer Research · 2008 · 158 citations · Full text

, , +17

1–5 of 61